Science: Our approach

De-risked drug development

Missing the target is the biggest risk for targeted drug delivery.

Many promising Antibody-Drug Conjugates failed because they failed to target. What is worse, these failures typically emerged at the later stages of clinical development. Such late-stage failures are a huge waste of time and money.

Targeting can be confirmed by means of in-life molecular imaging, but this demands high-level expertise and infrastructure.

At LinXis, molecular imaging is our bread and butter - and we apply it from the earliest stages of drug development onward.

Using molecular imaging we have extensively validated the targeting ability of our lead Fibrobody® in preclinical models - and we are all set to validate it in patients.

LinXis-fig-Targeting-by-Fibrobody.png

A truly pan-fibrotic drug delivery vector

The possibilities are endless

We have validated our lead Fibrobody® in numerous types of Fibrosis, demonstrating it to be a truly pan-fibrotic drug delivery vehicle.

Fibrobodies® can be functionalized with virtually all types of antifibrotic drugs and agents. Through our molecular imaging-guided development drug strategy we can quickly and efficiently come to effective diagnostic and therapeutic conjugates.

The impact of Fibrobodies®

Small, smart, and selective

Small enough to reach myofibroblasts, Fibrobodies® are species-cross-reactive

Cost-effective, simple design

Fibrobodies® can be produced quickly and in large quantities

Suitable for diagnosis and treatment

Fibrobodies® are a perfect delivery vehicle that can be equipped with any cargo

Selective for activated myofibroblasts

Extensively validated targeting ability